These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37888491)

  • 1. Molecular Mechanism of Labelling Functional Cysteines by Heterocyclic Thiones.
    Mihalovits LM; Kollár L; Bajusz D; Knez D; Bozovičar K; Imre T; Ferenczy GG; Gobec S; Keserű GM
    Chemphyschem; 2024 Jan; 25(1):e202300596. PubMed ID: 37888491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiscale Simulations of the Covalent Inhibition of the SARS-CoV-2 Main Protease: Four Compounds and Three Reaction Mechanisms.
    Grigorenko BL; Polyakov IV; Khrenova MG; Giudetti G; Faraji S; Krylov AI; Nemukhin AV
    J Am Chem Soc; 2023 Jun; 145(24):13204-13214. PubMed ID: 37294056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
    Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
    Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational details of molecular structure, spectroscopic properties, topological studies and SARS-Cov-2 enzyme molecular docking simulation of substituted triazolo pyrimidine thione heterocycles.
    El Sayed DS; Abdelrehim EM
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Nov; 261():120006. PubMed ID: 34098482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M
    Soulère L; Barbier T; Queneau Y
    Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.
    Banerjee S
    Biophys Chem; 2021 Feb; 269():106510. PubMed ID: 33285430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Warhead Modulations on the Covalent Inhibition of SARS-CoV-2 M
    Martí S; Arafet K; Lodola A; Mulholland AJ; Świderek K; Moliner V
    ACS Catal; 2022 Jan; 12(1):698-708. PubMed ID: 35036042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
    Wang Y; Gao Q; Yao P; Yao Q; Zhang J
    J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2.
    Paul AS; Islam R; Parves MR; Mamun AA; Shahriar I; Hossain MI; Hossain MN; Ali MA; Halim MA
    J Biomol Struct Dyn; 2022 Mar; 40(4):1639-1658. PubMed ID: 33047658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
    Ábrányi-Balogh P; Petri L; Imre T; Szijj P; Scarpino A; Hrast M; Mitrović A; Fonovič UP; Németh K; Barreteau H; Roper DI; Horváti K; Ferenczy GG; Kos J; Ilaš J; Gobec S; Keserű GM
    Eur J Med Chem; 2018 Dec; 160():94-107. PubMed ID: 30321804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Reversibility for Covalent Cysteine Protease Inhibitors Using Quantum Mechanics/Molecular Mechanics Free Energy Surfaces.
    Dos Santos AM; Oliveira ARS; da Costa CHS; Kenny PW; Montanari CA; Varela JJG; Lameira J
    J Chem Inf Model; 2022 Sep; 62(17):4083-4094. PubMed ID: 36044342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with α-Substituent Electrophiles Targeting Cysteine.
    Ai Y; Yang Z; Yang Z; Wan S; Huang C; Huang C; Li M; Li Z; Zhang J; Zhang T
    J Chem Inf Model; 2023 Jan; 63(2):493-506. PubMed ID: 36632804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2.
    Rieder GS; Nogara PA; Omage FB; Duarte T; Dalla Corte CL; da Rocha JBT
    Comput Biol Chem; 2023 Dec; 107():107956. PubMed ID: 37748316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design.
    Ramos-Guzmán CA; Ruiz-Pernía JJ; Tuñón I
    Chem Sci; 2021 Jan; 12(10):3489-3496. PubMed ID: 34163622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.